Parkinson's disease (PD) is clinically, pathologically, and genetically heterogeneous,
resisting distillation to a single, cohesive disorder. Instead, each affected individual develops …

The development of interventions to slow or halt the progression of Parkinson's disease
remains a priority for patients and researchers alike. To date, no agents have been shown to …

Multiple lines of evidence indicate that immune system dysfunction has a role in Parkinson
disease (PD); this evidence includes clinical and genetic associations between autoimmune …

The GBA gene encodes for the lysosomal enzyme glucocerebrosidase (GCase), which
maintains glycosphingolipid homeostasis. Approximately 5–15% of PD patients have …

Depression is one of the most important non-motor symptoms in Parkinson's disease (PD),
but its prevalence and related clinical characteristics are unclear. To this end, we performed …

The genetic landscape of Parkinson's disease (PD) is characterised by rare high penetrance
pathogenic variants causing familial disease, genetic risk factor variants driving PD risk in a …

Genetic studies have shown the association of Parkinson's disease with alleles of the major
histocompatibility complex,,. Here we show that a defined set of peptides that are derived …

Mutations in the glucocerebrosidase gene (GBA), which cause Gaucher disease, are also
potent risk factors for Parkinson's disease. We examined whether a genetic burden of …

The diagnosis of Parkinson's disease (PD) and atypical parkinsonian syndromes is difficult
due to the lack of reliable, easily accessible biomarkers. Multiple system atrophy (MSA) is a …

Parkinson's disease is a common, progressive neurodegenerative disorder, affecting 3% of
those older than 75 years of age. Clinically, Parkinson's disease (PD) is associated with …